Annotation (Toggle Detail/Summary View) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene-Chemical Interaction AnnotationsGene-Chemical Interaction Annotations
Gene-Chemical Interaction AnnotationsTerm | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (+)-pilocarpine | increases response to substance | ISO | RGD:10232 | 6480464 | BDKRB2 protein mutant form results in increased susceptibility to Pilocarpine | CTD | PMID:15196965 | (R)-noradrenaline | affects response to substance | ISO | RGD:10232 | 6480464 | BDKRB2 affects the susceptibility to Norepinephrine | CTD | PMID:12105144 | 17beta-estradiol | multiple interactions | ISO | RGD:737386 | 6480464 | [Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of BDKRB2 mRNA | CTD | PMID:19619570 | 17beta-estradiol | increases expression | ISO | RGD:737386 | 6480464 | Estradiol results in increased expression of BDKRB2 mRNA | CTD | PMID:19619570 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:737386 | 6480464 | [Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of BDKRB2 mRNA | CTD | PMID:19619570 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of BDKRB2 mRNA | CTD | PMID:22298810 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:737386 | 6480464 | Tetrachlorodibenzodioxin affects the expression of BDKRB2 mRNA | CTD | PMID:22298810 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:737386 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of BDKRB2 mRNA | CTD | PMID:11489354 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:737386 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of BDKRB2 mRNA | CTD | PMID:19619570 | 3',5'-cyclic GMP | multiple interactions | EXP | | 6480464 | [icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [valsartan results in increased abundance of Cyclic GMP] | CTD | PMID:16982965 | 5-fluorouracil | multiple interactions | ISO | RGD:737386 | 6480464 | TP53 protein affects the reaction [Fluorouracil results in increased expression of BDKRB2 mRNA] | CTD | PMID:15016801 | 6-oxo-prostaglandin F1alpha | affects abundance | ISO | RGD:10232 | 6480464 | BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha | CTD | PMID:16514058 | 6-oxo-prostaglandin F1alpha | multiple interactions | ISO | RGD:10232 | 6480464 | PD 123319 affects the reaction [BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha] | CTD | PMID:16514058 | amlodipine | increases response to substance | ISO | RGD:10232 | 6480464 | BDKRB2 results in increased susceptibility to Amlodipine | CTD | PMID:10523327 | atenolol | affects response to substance | ISO | RGD:737386 | 6480464 | BDKRB2 exon polymorphism affects the susceptibility to Atenolol | CTD | PMID:12640257 | atropine | multiple interactions | ISO | RGD:10232 | 6480464 | BDKRB2 affects the susceptibility to [Propranolol co-treated with Atropine] | CTD | PMID:10614985 | benazepril | increases activity | ISO | RGD:10232 | 6480464 | benazepril results in increased activity of BDKRB2 protein | CTD | PMID:15339989 | benazepril | multiple interactions | EXP | | 6480464 | [icatibant results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to benazepril | CTD | PMID:16982965 | benzo[a]pyrene | multiple interactions | ISO | RGD:10232 | 6480464 | Benzo(a)pyrene promotes the reaction [AHR protein binds to BDKRB2 promoter] | CTD | PMID:19654925 | calcium atom | multiple interactions | ISO | RGD:737386 | 6480464 | BDKRB2 protein affects the reaction [KNG1 protein affects the abundance of Calcium] | CTD | PMID:18054572 | calcium(0) | multiple interactions | ISO | RGD:737386 | 6480464 | BDKRB2 protein affects the reaction [KNG1 protein affects the abundance of Calcium] | CTD | PMID:18054572 | candesartan | decreases expression | EXP | | 6480464 | candesartan results in decreased expression of BDKRB2 mRNA | CTD | PMID:18796534 | capsaicin | multiple interactions | EXP | | 6480464 | Capsaicin inhibits the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates] | CTD | PMID:17347322 | capsaicin | multiple interactions | ISO | RGD:737386 | 6480464 | BDKRB2 affects the reaction [Capsaicin results in increased activity of TRPV1 protein]; more ... | CTD | PMID:15363968 | ceruletide | increases expression | ISO | RGD:10232 | 6480464 | Caerulein results in increased expression of BDKRB2 mRNA | CTD | PMID:21484880 | chondroitin sulfate | multiple interactions | EXP | | 6480464 | [icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Chondroitin Sulfates | CTD | PMID:21436127 | copper(2+) sulfate | increases expression | ISO | RGD:737386 | 6480464 | Copper Sulfate results in increased expression of BDKRB2 mRNA | CTD | PMID:19549813 | cyclophosphamide | affects expression | EXP | | 6480464 | Cyclophosphamide affects the expression of BDKRB2 mRNA | CTD | PMID:15576455 | dibutyl phthalate | increases expression | EXP | | 6480464 | Dibutyl Phthalate results in increased expression of BDKRB2 mRNA | CTD | PMID:21266533 | dichlorine | multiple interactions | EXP | | 6480464 | [Ozone co-treated with Chlorine] results in decreased expression of BDKRB2 mRNA | CTD | PMID:18636392 | enalapril | increases expression | EXP | | 6480464 | Enalapril results in increased expression of BDKRB2 protein; more ... | CTD | PMID:18190998 | fonofos | increases methylation | ISO | RGD:737386 | 6480464 | Fonofos results in increased methylation of BDKRB2 promoter | CTD | PMID:22847954 | formaldehyde | decreases expression | ISO | RGD:737386 | 6480464 | Formaldehyde results in decreased expression of BDKRB2 mRNA | CTD | PMID:20655997 | icatibant | multiple interactions | ISO | RGD:737386 | 6480464 | icatibant inhibits the reaction [KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein]; more ... | CTD | PMID:15140628 | icatibant | multiple interactions | EXP | | 6480464 | [icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Chondroitin Sulfates | CTD | PMID:21436127 | icatibant | multiple interactions | EXP | | 6480464 | [icatibant results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to benazepril; more ... | CTD | PMID:16982965 | icatibant | multiple interactions | EXP | | 6480464 | icatibant inhibits the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates] | CTD | PMID:17347322 | icatibant | multiple interactions | EXP | | 6480464 | [icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Streptozocin; more ... | CTD | PMID:17989505 | icatibant | multiple interactions | ISO | RGD:737386 | 6480464 | icatibant binds to and results in decreased activity of BDKRB2 protein | CTD | PMID:10666510 | icatibant | multiple interactions | EXP | | 6480464 | icatibant binds to and results in decreased activity of BDKRB2 protein | CTD | PMID:10666510 PMID:12727271 | irbesartan | affects response to substance | ISO | RGD:737386 | 6480464 | BDKRB2 exon polymorphism affects the susceptibility to irbesartan | CTD | PMID:12640257 | nitroprusside | affects response to substance | ISO | RGD:10232 | 6480464 | BDKRB2 affects the susceptibility to Nitroprusside | CTD | PMID:10614985 | ozone | multiple interactions | EXP | | 6480464 | [Ozone co-treated with Chlorine] results in decreased expression of BDKRB2 mRNA | CTD | PMID:18636392 | parathion | increases methylation | ISO | RGD:737386 | 6480464 | Parathion results in increased methylation of BDKRB2 promoter | CTD | PMID:22847954 | PD123319 | multiple interactions | ISO | RGD:10232 | 6480464 | PD 123319 affects the reaction [BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha] | CTD | PMID:16514058 | perindopril | affects expression | EXP | | 6480464 | Perindopril affects the expression of BDKRB2 protein | CTD | PMID:18806609 | phenobarbital | affects expression | ISO | RGD:737386 | 6480464 | Phenobarbital affects the expression of BDKRB2 mRNA | CTD | PMID:19159669 | phenylephrine | affects response to substance | ISO | RGD:10232 | 6480464 | BDKRB2 affects the susceptibility to Phenylephrine | CTD | PMID:10614985 | phenylephrine | increases expression | EXP | | 6480464 | Phenylephrine results in increased expression of BDKRB2 mRNA | CTD | PMID:18158353 | propranolol | multiple interactions | ISO | RGD:10232 | 6480464 | BDKRB2 affects the susceptibility to [Propranolol co-treated with Atropine] | CTD | PMID:10614985 | resveratrol | decreases expression | ISO | RGD:737386 | 6480464 | resveratrol results in decreased expression of BDKRB2 mRNA; more ... | CTD | PMID:18089832 | streptozocin | multiple interactions | EXP | | 6480464 | [icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Streptozocin | CTD | PMID:17989505 | streptozocin | increases expression | ISO | RGD:10232 | 6480464 | Streptozocin results in increased expression of BDKRB2 mRNA | CTD | PMID:19516248 | terbufos | increases methylation | ISO | RGD:737386 | 6480464 | terbufos results in increased methylation of BDKRB2 promoter | CTD | PMID:22847954 | tetrachloromethane | decreases expression | ISO | RGD:10232 | 6480464 | Carbon Tetrachloride results in decreased expression of BDKRB2 mRNA | CTD | PMID:17484886 | tetrachloromethane | increases expression | EXP | | 6480464 | Carbon Tetrachloride results in increased expression of BDKRB2 protein | CTD | PMID:18054572 | trans-resveratrol | decreases expression | ISO | RGD:737386 | 6480464 | resveratrol results in decreased expression of BDKRB2 mRNA; more ... | CTD | PMID:18089832 | valsartan | multiple interactions | EXP | | 6480464 | [icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [valsartan results in increased abundance of Cyclic GMP]; more ... | CTD | PMID:16982965 | vincristine | multiple interactions | EXP | | 6480464 | [icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Vincristine | CTD | PMID:17989505 | zinc atom | increases expression | EXP | | 6480464 | Zinc deficiency results in increased expression of BDKRB2 mRNA | CTD | PMID:12672911 | zinc(0) | increases expression | EXP | | 6480464 | Zinc deficiency results in increased expression of BDKRB2 mRNA | CTD | PMID:12672911 | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gene Ontology AnnotationsMolecular Pathway AnnotationsDisease Annotations
|
|
|
Gene-Chemical Interaction Annotations
|
|
|
Gene Ontology Annotations
|
|
|
|
|
Molecular Pathway Annotations
|
|
| External Database Links | |
| KEGG Pathway | Calcium signaling pathway |
| Chagas disease (American trypanosomiasis) | |
| Complement and coagulation cascades | |
| Endocrine and other factor-regulated calcium reabsorption | |
| Neuroactive ligand-receptor interaction | |
| Regulation of actin cytoskeleton | |
| Pathway Interaction Database | Direct p53 effectors (PID:200120) |
| Validated transcriptional targets of deltaNp63 isoforms (PID:200186) | |
References - curated| 1. |
Abadir PM, etal., Hypertension. 2006 Aug;48(2):316-22. Epub 2006 Jun 5. |
| 2. |
Abdouh M, etal., Br J Pharmacol. 2008 May;154(1):136-43. Epub 2008 Mar 3. |
| 3. |
Akbary AM, etal., Immunopharmacology. 1996 Jun;33(1-3):238-42. |
| 4. |
Becker KG, etal., Nat Genet 2004 May;36(5):431-2. |
| 5. |
Bertram CM, etal., J Leukoc Biol. 2009 Mar;85(3):544-52. Epub 2008 Nov 26. |
| 6. |
Bujalska M and Makulska-Nowak H, Neuro Endocrinol Lett. 2009 Mar;30(1):144-52. |
| 7. |
Campos MM, etal., Synapse. 2005 Dec 1;58(3):184-92. |
| 8. |
Chen CT, etal., Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1261-7. |
| 9. |
Chopra B, etal., J Physiol. 2005 Feb 1;562(Pt 3):859-71. Epub 2004 Dec 2. |
| 10. |
Cloutier F, etal., Br J Pharmacol. 2002 Apr;135(7):1641-54. |
| 11. |
Cote J, etal., Neuropeptides. 2010 Apr;44(2):177-85. Epub 2010 Jan 18. |
| 12. |
Dabek J, etal., Scand Cardiovasc J. 2007 Dec;41(6):391-6. |
| 13. |
Duchene J, etal., Biochem Biophys Res Commun. 2005 Jan 28;326(4):894-900. |
| 14. |
Duchene J, etal., J Biol Chem. 2002 Oct 25;277(43):40375-83. Epub 2002 Aug 12. |
| 15. |
Duka A, etal., Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E268-74. Epub 2006 Feb 28. |
| 16. |
Ellis KM, etal., Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):166-78. Epub 2004 Jan 15. |
| 17. |
Feletou M, etal., J Pharmacol Exp Ther. 1995 Jun;273(3):1078-84. |
| 18. |
Fischer LG, etal., Anesth Analg. 2000 Mar;90(3):625-31. |
| 19. |
Gama Landgraf R, etal., Inflamm Res. 2004 Feb;53(2):78-83. Epub 2004 Jan 26. |
| 20. |
GOA data from the GO Consortium |
| 21. |
Grilo A, etal., Pharmacogenet Genomics. 2011 Jan;21(1):10-7. |
| 22. |
Hopkinson NS, etal., Am J Clin Nutr. 2006 Apr;83(4):912-7. |
| 23. |
Imai C, etal., Clin Exp Hypertens 2005 Jan;27(1):59-69. |
| 24. |
Kusser B, etal., Biol Chem. 2001 May;382(5):885-9. |
| 25. |
Kwitek AE, etal., Genome Res. 2004 Apr;14(4):750-7 |
| 26. |
Lee YJ and Tsai JC, Metabolism. 2001 Nov;50(11):1346-50. |
| 27. |
Liesmaa I, etal., J Cell Physiol. 2009 Nov;221(2):359-66. |
| 28. |
Majima M, etal., Br J Pharmacol. 1997 Jun;121(4):723-30. |
| 29. |
McEachern AE, etal., Proc Natl Acad Sci U S A 1991 Sep 1;88(17):7724-8. |
| 30. |
MGD data from the GO Consortium |
| 31. |
Mukae S, etal., Hypertension. 2000 Jul;36(1):127-31. |
| 32. |
Mukae S, etal., J Hum Hypertens. 2002 Dec;16(12):857-63. |
| 33. |
NCBI rat LocusLink and RefSeq merged data July 26, 2002 |
| 34. |
Ongali B, etal., J Comp Neurol 2003 Jul 7;461(4):506-19. |
| 35. |
Pesquero JB, etal., J Biol Chem 1994 Oct 28;269(43):26920-5. |
| 36. |
Petcu M, etal., Int Immunopharmacol. 2008 Feb;8(2):188-96. Epub 2007 Sep 29. |
| 37. |
Pipeline to import KEGG annotations from KEGG into RGD Pathway Ontology |
| 38. |
Poole S, etal., Br J Pharmacol. 1999 Feb;126(3):649-56. |
| 39. |
Qadri F, etal., Can J Physiol Pharmacol 2002 Apr;80(4):258-63. |
| 40. |
Rajakulasingam K, etal., J Physiol. 1991 Jun;437:577-87. |
| 41. |
Rastelli VM, etal., Peptides. 2008 Mar;29(3):404-11. Epub 2007 Dec 7. |
| 42. |
RGD automated import pipeline for gene-chemical interactions |
| 43. |
Silva AR, etal., Br J Pharmacol. 1999 May;127(2):569-75. |
| 44. |
Spillmann F, etal., Int Immunopharmacol 2002 Dec;2(13-14):1823-32. |
| 45. |
Tan Y, etal., Am J Physiol Renal Physiol. 2007 Oct;293(4):F1026-35. Epub 2007 Jun 27. |
| 46. |
Taraseviciene-Stewart L, etal., Peptides. 2005 Aug;26(8):1292-300. |
| 47. |
Turner P, etal., J Allergy Clin Immunol. 2001 Jan;107(1):105-13. |
| 48. |
Wang DZ, etal., Hypertension. 1997 Jan;29(1 Pt 2):488-93. |
| 49. |
Woo SW, etal., J Clin Pharm Ther. 2009 Oct;34(5):561-7. |
| 50. |
Yuhki K, etal., J Pharmacol Exp Ther. 2004 Dec;311(3):1218-24. Epub 2004 Aug 17. |
References - uncurated| PubMed | 10085087 |
| 11686492 | |
| 12025970 | |
| 12435802 | |
| 12444060 | |
| 12558524 | |
| 12558526 | |
| 12623134 | |
| 12639805 | |
| 12694402 | |
| 12791684 | |
| 12923406 | |
| 14753436 | |
| 14766673 | |
| 14766794 | |
| 15001555 | |
| 15708952 | |
| 16513137 | |
| 18264983 | |
| 18302192 | |
| 18632797 | |
| 19017652 | |
| 19027830 | |
| 19544046 | |
| 19889854 | |
| 19954757 | |
| 20198577 | |
| 20345876 | |
| 20531238 | |
| 20637711 | |
| 20883789 | |
| 21232147 | |
| 21986469 | |
| 22739815 | |
| 22862305 | |
| 22877648 | |
| 23132855 | |
| 8086459 | |
| 8394991 | |
| 8652530 |
RGD Disease Portals| Bdkrb2 has been annotated in the following RGD Disease Portals. |
|||||||
 |
| ||||||
 |
| ||||||
 |
| ||||||
 |
| ||||||
 |
| ||||||
 |
| ||||||
 |
| ||||||
Comparative Map Data| Bdkrb2 (Rattus norvegicus) |
|
|||||||||||||||||||||||||||||||||||
| BDKRB2 (Homo sapiens) |
|
|||||||||||||||||||||||||||||||||||
| Bdkrb2 (Mus musculus) |
|
Position Markers| PMC150944P1 |
|
||||||||||||||||||||||||||||||
| L27595 |
|
||||||||||||||||||||||||||||||
| PMC126639P3 |
|
||||||||||||||||||||||||||||||
| RH94464 |
|
QTLs in Region (RGSC Genome Assembly v3.4)| The following QTLs overlap with this region. |  | Full Report | | CSV | | TAB | | Printer | | Gviewer |
Nucleotide Sequences| Nucleotide RefSeqs | NM_001270713 | (Get FASTA) | Search GEO for Microarray Profiles |
| NM_173100 | (Get FASTA) | Search GEO for Microarray Profiles | |
| GenBank Nucleotide | AABR06046090 | (Get FASTA) | Search GEO for Microarray Profiles |
| AAHX01046343 | (Get FASTA) | Search GEO for Microarray Profiles | |
| AAHX01046344 | (Get FASTA) | Search GEO for Microarray Profiles | |
| CH474034 | (Get FASTA) | Search GEO for Microarray Profiles | |
| L26171 | (Get FASTA) | Search GEO for Microarray Profiles | |
| L26173 | (Get FASTA) | Search GEO for Microarray Profiles | |
| M59967 | (Get FASTA) | Search GEO for Microarray Profiles | |
| X69681 | (Get FASTA) | Search GEO for Microarray Profiles | |
| X80187 | (Get FASTA) | Search GEO for Microarray Profiles | |
| X80189 | (Get FASTA) | Search GEO for Microarray Profiles | |
| X80190 | (Get FASTA) | Search GEO for Microarray Profiles |
| RefSeq Acc Id: | NM_173100 | ||||||||||||||||||||
| RefSeq Status: | VALIDATED | ||||||||||||||||||||
| Type: | CODING | ||||||||||||||||||||
| Protein Acc Id: | NP_775123 | ||||||||||||||||||||
| Position: |
|
Protein Sequences| Protein RefSeqs | NP_001257642 | (Get FASTA) |
| NP_775123 | (Get FASTA) | |
| GenBank Protein | AAA16425 | (Get FASTA) |
| AAA16426 | (Get FASTA) | |
| AAA62492 | (Get FASTA) | |
| CAA49361 | (Get FASTA) | |
| EDL97606 | (Get FASTA) | |
| EDL97607 | (Get FASTA) | |
| P25023 | (Get FASTA) |
Strain Sequence Variants
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
External Database Links| Database | Acc Id | Source(s) |
| Ensembl Genes | ENSRNOG00000047300 | ENTREZGENE, UniProtKB/Swiss-Prot |
| Ensembl Protein | ENSRNOP00000064715 | ENTREZGENE, UniProtKB/Swiss-Prot |
| ENSRNOP00000064990 | UniProtKB/TrEMBL | |
| Ensembl Transcript | ENSRNOT00000071735 | ENTREZGENE, UniProtKB/Swiss-Prot |
| ENSRNOT00000074621 | UniProtKB/TrEMBL | |
| Entrez Gene | 25245 | ENTREZGENE |
| Germonline | ENSRNOG00000004454 | UniProtKB/Swiss-Prot |
| HomoloGene Group ID | 519 | ENTREZGENE |
| InterPro | 7TM_GPCR_Rhodpsn | UniProtKB/Swiss-Prot |
| B2_bradkn_rcpt | UniProtKB/Swiss-Prot | |
| Brdyknn_rcpt | UniProtKB/Swiss-Prot | |
| GPCR_Rhodpsn_supfam | UniProtKB/Swiss-Prot | |
| IPI | IPI00209884 | UniProtKB/Swiss-Prot |
| IPI00231807 | UniProtKB/Swiss-Prot | |
| KEGG Report | rno:25245 | ENTREZGENE, UniProtKB/Swiss-Prot |
| Pfam | 7tm_1 | UniProtKB/Swiss-Prot |
| PharmGKB | BDKRB2 | RGD |
| PRINTS | BRADYKININR | UniProtKB/Swiss-Prot |
| BRADYKINNB2R | UniProtKB/Swiss-Prot | |
| GPCRRHODOPSN | UniProtKB/Swiss-Prot | |
| PROSITE | G_PROTEIN_RECEP_F1_1 | UniProtKB/Swiss-Prot |
| G_PROTEIN_RECEP_F1_2 | UniProtKB/Swiss-Prot | |
| UniGene | Rn.9845 | ENTREZGENE |
| UniProt | BKRB2_RAT | UniProtKB/Swiss-Prot |
| G3V942_RAT | UniProtKB/TrEMBL |
Nomenclature History| Date | Current Symbol | Current Name | Previous Symbol | Previous Name | Description | Reference | Status |
|---|---|---|---|---|---|---|---|
| 2008-09-25 | Bdkrb2 | bradykinin receptor B2 | Bdkrb2 | bradykinin receptor, beta 2 | Nomenclature updated to reflect human and mouse nomenclature | 10779 | APPROVED |
| 2006-03-30 | Bdkrb2 | bradykinin receptor, beta 2 | bradykinin receptor b2 | Name updated | 10779 | APPROVED | |
| 2002-06-10 | Bdkrb2 | Bradykinin receptor B2 | Symbol and Name status set to approved | 1490 | APPROVED |
RGD Curation Notes| Note Type | Note | Reference |
|---|---|---|
| gene_expression | expressed in uterus, vas deferens, kidney, lung, heart, ileum, testis, and brain | 631709 |
| gene_function | receptor | 631709 |
| gene_process | involved in pain response | 631709 |
| gene_product | member of seven transmembrane G protein-coupled superfamily of receptors | 631709 |
| gene_regulation | expression is higher in unstimulated, cultured cardiac fibroblasts from adult SHR rats than in those from WKY rats. After exposure of cells to IL-1 beta, expression is enhanced in cells of both strains to equivalent levels. | 1358958 |
| gene_transcript | mRNA exists in two splicing variants | 631790 |
| More on Bdkrb2 | |
|
Entrez Gene |
|
Ensembl Gene |
| Genome Browser |
|
NCBI Map Viewer |
|
Vista |
|
Vista + UCSC |
| RGD Object Information | |
| RGD ID: | 2201 |
| Created: | 2000-05-25 |
| Species: | Rattus norvegicus |
| Last Modified: | 2013-05-14 |
| Status: | ACTIVE |
© Bioinformatics Program, HMGC at the Medical College of Wisconsin
RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.